Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the relationship between fractionated exhaled nitric oxide, peripheral eosinophils, and plasma citrulline and ß-alanine in patients with eosinophilic esophagitis (EoE) compared to those without EoE.
The hypothesis is that a combination of elevated fractional exhaled nitric oxide, increased peripheral eosinophils, and elevated plasma citrulline and ß-alanine is associated with active EoE.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active eosinophilic esophagitis | |||
| Eosinophilic esophagitis in remission | |||
| No eosinophilic esophagitis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Fractionated exhaled nitric oxide (FeNO) level | The FeNO measurement will be performed using a hand-held analyzer, the NIOX MINO (Aerocrine, Sweden). During this non-invasive procedure the patient is asked to perform a 4-6 second single-breath exhalation into the NIOX MINO, which measures FeNO in 100s with an electrochemical sensor. | baseline (day of first endoscopy) |
| Fractionated exhaled nitric oxide (FeNO) level | The FeNO measurement will be performed using a hand-held analyzer, the NIOX MINO (Aerocrine, Sweden). During this non-invasive procedure the patient is asked to perform a 4-6 second single-breath exhalation into the NIOX MINO, which measures FeNO in 100s with an electrochemical sensor. | at about 4-12 weeks (day of second endoscopy) |
| Measure | Description | Time Frame |
|---|---|---|
| Esophageal eosinophil counts as assessed by biopsy | baseline (day of first endoscopy) | |
| Esophageal eosinophil counts as assessed by biopsy | at about 4-12 weeks (day of second endoscopy) | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All patients will be recruited from the outpatient clinic of the Pediatric Gastroenterology Division of The University of Texas Health and Science Center at Houston.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tu T Mai, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36574003 | Result | Josyabhatla R, Abrenica C, Mai T, Hashmi SS, Liu Y, Mosquera R, Van Arsdall M, Navarro F, Tchakarov A, Tatevian N, Wu G, Rhoads JM. Plasma Biomarkers and Fractional Exhaled Nitric Oxide in the Diagnosis of Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 Jan 1;76(1):59-65. doi: 10.1097/MPG.0000000000003634. Epub 2022 Oct 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Blood eosinophil counts as assessed by complete blood count (CBC) |
| baseline (day of first endoscopy) |
| Blood eosinophil counts as assessed by complete blood count (CBC) | at about 4-12 weeks (day of second endoscopy) |
| Plasma beta-alanine level as assessed by high-performance liquid chromatography | baseline (day of first endoscopy) |
| Plasma beta-alanine level as assessed by high-performance liquid chromatography | at about 4-12 weeks (day of second endoscopy) |
| Plasma citrulline level as assessed by high-performance liquid chromatography | baseline (day of first endoscopy) |
| Plasma citrulline level as assessed by high-performance liquid chromatography | at about 4-12 weeks (day of second endoscopy) |
| ID | Term |
|---|---|
| D057765 | Eosinophilic Esophagitis |
| ID | Term |
|---|---|
| D004941 | Esophagitis |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D005759 | Gastroenteritis |
| D004802 | Eosinophilia |
| D007960 | Leukocyte Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided